Return on invested capital

Return on invested capital

Although Dura Pharmaceuticals' $153 million follow-on ranks among the top three biotech follow-ons, last week's closing was only the tip of the equity iceberg for the company. Over the last 16 months, DURA has tapped the public markets three times, raising $356 million in aggregate. In the last seven months, DURA has pocketed $291 million.

Those All-Star numbers prompted Ebb & Flow to poll sell-side analysts who follow DURA. All concurred on one point - the company has a great track record for

Read the full 873 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE